JP2021517588A5 - - Google Patents

Info

Publication number
JP2021517588A5
JP2021517588A5 JP2020571917A JP2020571917A JP2021517588A5 JP 2021517588 A5 JP2021517588 A5 JP 2021517588A5 JP 2020571917 A JP2020571917 A JP 2020571917A JP 2020571917 A JP2020571917 A JP 2020571917A JP 2021517588 A5 JP2021517588 A5 JP 2021517588A5
Authority
JP
Japan
Prior art keywords
cancer
cells
pharmaceutical composition
cxcr4
antigen
Prior art date
Application number
JP2020571917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517588A (ja
JP7561631B2 (ja
JPWO2019175802A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/052042 external-priority patent/WO2019175802A1/en
Publication of JP2021517588A publication Critical patent/JP2021517588A/ja
Publication of JP2021517588A5 publication Critical patent/JP2021517588A5/ja
Publication of JPWO2019175802A5 publication Critical patent/JPWO2019175802A5/ja
Priority to JP2024067425A priority Critical patent/JP2024105305A/ja
Application granted granted Critical
Publication of JP7561631B2 publication Critical patent/JP7561631B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571917A 2018-03-13 2019-03-13 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 Active JP7561631B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024067425A JP2024105305A (ja) 2018-03-13 2024-04-18 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642313P 2018-03-13 2018-03-13
US62/642,313 2018-03-13
PCT/IB2019/052042 WO2019175802A1 (en) 2018-03-13 2019-03-13 Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024067425A Division JP2024105305A (ja) 2018-03-13 2024-04-18 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体

Publications (4)

Publication Number Publication Date
JP2021517588A JP2021517588A (ja) 2021-07-26
JP2021517588A5 true JP2021517588A5 (https=) 2022-06-06
JPWO2019175802A5 JPWO2019175802A5 (https=) 2022-06-06
JP7561631B2 JP7561631B2 (ja) 2024-10-04

Family

ID=66286540

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571917A Active JP7561631B2 (ja) 2018-03-13 2019-03-13 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体
JP2024067425A Withdrawn JP2024105305A (ja) 2018-03-13 2024-04-18 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024067425A Withdrawn JP2024105305A (ja) 2018-03-13 2024-04-18 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体

Country Status (7)

Country Link
US (1) US20230181635A1 (https=)
EP (1) EP3765519B1 (https=)
JP (2) JP7561631B2 (https=)
KR (1) KR102693317B1 (https=)
CN (1) CN112513079A (https=)
ES (1) ES2973728T3 (https=)
WO (1) WO2019175802A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN117715647A (zh) * 2021-04-08 2024-03-15 埃迪瓦生物治疗公司 用nk细胞和cd38靶向抗体治疗癌症
CN115836666B (zh) * 2021-09-20 2024-11-01 上海中医药大学附属龙华医院 原位骨肉瘤和肺转移瘤小鼠模型及其制法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2532399T3 (es) 2003-03-05 2015-03-26 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
KR101722261B1 (ko) * 2006-10-02 2017-04-03 메다렉스, 엘.엘.시. Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
EA201071300A1 (ru) 2008-05-14 2011-06-30 Эли Лилли Энд Компани Антитела к cxcr4
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
US8877182B2 (en) * 2009-03-26 2014-11-04 Cellprotect Nordic Pharmaceuticals Ab Expansion of NK cells
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
WO2013013025A2 (en) 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
SG11201401386XA (en) 2011-11-09 2014-10-30 Bristol Myers Squibb Co Treatment of hematologic malignancies with an anti-cxcr4 antibody
PE20160671A1 (es) 2013-08-02 2016-07-09 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
EP3066129B1 (en) 2013-11-06 2019-06-19 Bristol-Myers Squibb Company Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody
EP3212227B1 (en) * 2014-10-28 2020-01-15 Children's University Hospital Tübingen Treatment of pediatric bcp-all patients with an anti-kir antibody
US10813952B2 (en) * 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
EP3307778A1 (en) 2015-06-12 2018-04-18 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途

Similar Documents

Publication Publication Date Title
JP2021516045A5 (https=)
CN102264385B (zh) 含特异性识别cd38的抗体和苯丙氨酸氮芥的抗肿瘤组合
JP2018516969A5 (https=)
JP6215429B2 (ja) Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ
JP6130871B2 (ja) Ｃｄ３８を特異的に認識する抗体とビンクリスチンとを含有する抗腫瘍組合せ
JP2019533981A5 (https=)
CN102264386A (zh) 含特异性识别cd38的抗体和阿糖胞苷的抗肿瘤组合
CN107148285A (zh) 吡咯并苯并二氮杂*‑抗体缀合物
CN103282050A (zh) 包含特异性识别cd38的抗体和硼替佐米的抗肿瘤组合
WO2016204193A1 (ja) 抗がん剤
CN106659772A (zh) 在疾病和紊乱的治疗中调节肾酶的组合物和方法
CN112292128A (zh) Ep4抑制剂和其用途
US20220411512A1 (en) Combination treatment for cancer
JP2021517588A5 (https=)
JP2022526841A5 (https=)
JP2024105305A (ja) 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体
TW202102216A (zh) 抗腫瘤組合物
CN114867493B (zh) Kir3dl3是免疫系统的抑制性受体及其用途
TW202541808A (zh) 抗癌組合治療
JPWO2019175802A5 (https=)
JP2012025694A (ja) 癌治療剤
EP2968539A1 (en) Combination/adjuvant therapy for wt-1-positive disease
WO2019149219A1 (zh) 抗-cd3免疫毒素联合抗-pd-l1单域抗体治疗癌症的应用
RU2827900C1 (ru) Kir3dl3 - ингибирующий рецептор иммунной системы и его применение
HK40120537A (zh) 抗肿瘤组合物